Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment

Journal of Rheumatology

Volumn 32, Issue SUPPL. 75, 2005, Pages 6-21

  Mease, Philip ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Seattle Rhumatology Associates   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

Author keywords

Fatigue; Fibromyalgia; Neurohormone; Neurotransmitter; Pain; Sleep

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BIOGENIC AMINE; CITALOPRAM; CYCLOBENZAPRINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXEPIN; DULOXETINE; FLUOXETINE; MILNACIPRAN; MODAFINIL; MUSCLE RELAXANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PRAMIPEXOLE; PREGABALIN; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SOMATOMEDIN C; SUBSTANCE P; TRICYCLIC ANTIDEPRESSANT AGENT; TROPISETRON; ZOLPIDEM; ZOPICLONE;

ACUPUNCTURE; BEHAVIOR THERAPY; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL RESEARCH; COGNITIVE THERAPY; CONFERENCE PAPER; DIZZINESS; DRUG DEPENDENCE; EARLY DIAGNOSIS; EXERCISE; FIBROMYALGIA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MASSAGE; NEUROENDOCRINE DISEASE; NEUROLOGY; NEUROTRANSMITTER RELEASE; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATHOGENESIS; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRY; RHEUMATOLOGY; SOMNOLENCE; STRESS; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED STATES; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; REVIEW; SYNDROME;

FIBROMYALGIA; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); SYNDROME;

EID: 23444450943     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (140)

1. Clauw DJ. Elusive syndromes: treating the biologic basis of fibromyalgia and related syndromes. Cleve Clin J Med 2001;68:832-4.
2. Bennett R. Fibromyalgia, chronic fatigue syndrome, and myofascial pain. Curr Opin Rheumatol 1998;10:95-103.
3. Gowers WR. Lumbago: Its lessons and analogues. BMJ 1904;1:117-21.
4. Smythe HA, Moldofsky H. Two contributions to understanding the "fibrositis" syndrome. Bull Rheum Dis 1978;26:928-31.
5. Barkhuizen A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am 2002;28:261-90.
6. Bennett RM. The rational management of fibromyalgia patients. Rheum Dis Clin North Am 2002;28:181-99.
7. Bennett RM. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999;74:385-98.
8. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990;33:160-72.
9. Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999;26:408-12.
10. Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM. Clinical characteristics of fibrositis. I. A "blinded", controlled study of symptoms and tender points. Arthritis Rheum 1983;26:817-24.
11. Goldenberg DL. Fibromyalgia and related syndromes. In: Klippel JH, Dieppe PA, Arnett FC, et al, editors. Rheumatology. 2nd ed. St. Louis: Mosby; 1998:15.1-15.12.
12. Bennett RM. Fibromyalgia. In: Wall PD, Melzack R, editors. Textbook of pain. 4th ed. London: Harcourt Publishers, Churchill Livingstone; 1999:579-601.
13. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000;160:221-7.
14. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001;134:868-81.
15. Wolfe F. The fibromyalgia syndrome: a consensus report on fibromyalgia and disability. J Rheumatol 1996;23:534-9.
16. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol 2003;17:685-701.
17. Crofford LJ, Clauw DJ. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum 2002;46:1136-8.
18. Croft P, Rigby A, Boswell R, Scholium J, Silman A. The prevalence of chronic widespread pain in the general population. J Rheumatol 1993;20:710-3.
19. Wolfe F, Ross K, Anderson J. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
20. Goldenberg DL, Simms RW, Geiger A, Komaroff AL. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum 1990;33:381-7.
21. Brecher LS, Cymet TC. A practical approach to fibromyalgia. J Am Osteopath Assoc 2001;101 Suppl pt 2:S12-S17.
22. Menninger H. Other pain syndromes to be differentiated from fibromyalgia. Z Rheumatol 1998;57 Suppl 2:56-60.
23. Millea PJ, Holloway RL. Treating fibromyalgia. Am Fam Physician 2000;62:1575-1582;1587.
24. Fassbender K, Samborsky W, Kellner M, Muller W, Lautenbacher S. Tender points, depressive and functional symptoms: comparison between fibromyalgia and major depression. Clin Rheumatol 1997;16:76-9.
25. Bennett RM. Fibromyalgia and the disability dilemma. A new era in understanding a complex, multidimensional pain syndrome. Arthritis Rheum 1996;39:1627-34.
26. Greenfield S, Fitzcharles MA, Esdaile JM. Reactive fibromyalgia syndrome. Arthritis Rheum 1992;35:678-81.
27. Wolfe F, Anderson J, Harkness D, et al. Health status and disease severity in fibromyalgia: results of a six-center longitudinal study. Arthritis Rheum 1997;40:1571-9.
28. Burckhardt CS, Clark SR, Bennett RM. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993;20:475-9.
29. Martinez JE, Ferraz MB, Sato EI, Atra E. Fibromyalgia versus rheumatoid arthritis: a longitudinal comparison of the quality of life. J Rheumatol 1995;22:270-4.
30. Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003;23:104-7.
31. Klein R, Beansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology 1992;17:593-8.
32. Werle E, Fisher H, Muller A, et al. Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol 2001;28:595-600.
33. Daoud KF, Barkhuizen A. Rheumatic mimics and selected triggers of fibromyalgia. Curr Pain Headache Rep 2002;6:284-8.
34. Wolfe F, Cathey MA, Kleinheksel SM. Fibrositis (fibromyalgia) in rheumatoid arthritis. J Rheumatol 1984;11:814-8.
35. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 1994;37:1181-8.
36. Bonafede RP, Downey DC, Bennett RM. An association of fibromyalgia with primary Sjögren's syndrome: a prospective study of 72 patients. J Rheumatol 1995;22:133-6.
37. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997;40:446-52.
38. Dubner R, Hargreaves KM. The neurobiology of pain and its modulation. Clin J Pain 1989;5 Suppl 2:S1-4.
39. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6.
40. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol 1997;24:555-9.
41. Bourgoin S, Pohl M, Mauborgne A, et al. Monoaminergic control of the release of calcitonin gene-related peptide- and substance P-like materials from rat spinal cord slices. Neuropharmacology 1993;32:633-40.
42. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000;12 Suppl 1:2-19.
43. Juhl JH. Fibromyalgia and the serotonin pathway. Altern Med Rev 1998;3:367-75.
44. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601.
45. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997;40:1928-39.
46. Larson AA, Giovengo SL, Russell IJ, Michalek JE. Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000;87:201-11.
47. Hirose K, Chan PH. Blockade of glutamate excitotoxicity and its clinical applications. Neurochem Res 1993;18:479-83.
48. Riedel W, Neeck G. Nociception, pain, and antinociception: current concepts. J Rheumatol 2001;60:404-15.
49. Schwarz MJ, Spath M, Muller-Bardorff H, Pongratz DE, Bondy B, Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 1999;259:196-8.
50. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol 2003;463:235-72.
51. Goldenberg DL. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol 1993;5:199-208.
52. Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol 2000;113 Suppl:8-I2.
53. Geenen R, Jacobs JW, Bijlsma JW. Evaluation and management of endocrine dysfunction in fibromyalgia. Rheum Dis Clin North Am 2002;28:389-404.
54. McCain GA, Tube KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol 1989;16 Suppl 19:154-7.
55. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469-74.
56. Adler GK, Manfredsdottir VF, Creskoff KW. Neuroendocrine abnormalities in fibromyalgia. Curr Pain Headache Rep 2002;6:289-98.
57. Crofford LJ, Engleberg NC, Demitrack MA. Neurohormonal perturbations in fibromyalgia. Baillieres Clin Rheumatol 1996;10:365-78.
58. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2001;429:161-76.
59. Wallace DJ, Linker-Israeli M, Hallegua D, et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology Oxford 2001;40:743-9.
60. Salemi S, Rethage J, Wollina U, et al. Detection of interleukin 1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha in skin of patients with fibromyalgia. J Rheumatol 2003;30:146-50.
61. Johansson G, Risberg J, Rosenhall U, Orndahl G, Svennerholm L, Nystrom S. Cerebral dysfunction in fibromyalgia: evidence from regional cerebral blood flow measurements, otoneurological tests and cerebrospinal fluid analysis. Acta Psychiatr Scand 1995;91:86-94.
62. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995;38:926-38.
63. Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000;43:2823-33.
64. Gur A, Karakoc M, Erdogan S, Nas K, Cevik R, Sarac AJ. Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002;20:753-60.
65. Bradley LA, McKendree-Smith NL, Alberts KR, Alarcon GS, Mountz JM, Deutsch G. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep 2000;2:141-8.
66. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. Psychosomatics 1999;40:57-63.
67. Gendreau RM, Mease PJ, Rao SR, et al. Milnacipran: A potential new treatment of fibromyalgia [abstract]. Arthritis Rheum 2003;48 Suppl:S616.
68. Henriksson C, Gundmark I, Bengtsson A, Ek AC. Living with fibromyalgia: consequences for everyday life. Clin J Pain 1992;8:138-44.
69. Littlejohn GO. A database for fibromyalgia. Medical Pain Education Website. [Internet] Accessed April 20, 2005. Available from: http://websites.golden-orb.com/pain-education/100130.php
70. Burckhardt CS, Clark SR, Bennett RM. A comparison of pain perceptions in women with fibromyalgia and rheumatoid arthritis: relationship to depression and pain extent. Arthritis Care Res 1992;5:216-22.
71. Mengshoel AM, Forre O. Pain and fatigue in patients with rheumatic disorders. Clin Rheumatol 1993;12:515-21.
72. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38.
73. Martinez-Lavin M, Lopez S, Medina M, Nava A. Use of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaire in patients with fibromyalgia. Semin Arthritis Rheum 2003;32:407-11.
74. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981;11:151-71.
75. Gracely RH, Grant MA, Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003;17:593-609.
76. Sinclair D, Starz TW, Turk DC. The Manual Tender Point Survey. National Fibromyalgia Association Web site. [Internet] Accessed April 20, 2005. Available from: http://fmaware.org/doctor/tenderpt.htm
77. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993;42:93-9.
78. Smets EM, Garssen B, Bonke B, De Haes JCJM. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
79. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003;1:79.
80. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-3.
81. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well-being: The Medical Outcomes Study approach. Durham, NC: Duke University Press; 1992:235-59.
82. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106:337-45.
83. Turk DC, Dworkin RH. What should be the core outcomes in chronic pain clinical trials? Arthritis Res Ther 2004;6:151-4.
84. Ehrlich GE, Khaltaev NG. Low back pain initiative. Geneva: World Health Organization; 1999.
85. Ware JEJ, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36): Conceptual framework and item selection. Medical Care 1992;30:473-83.
86. Neumann L, Berzak A, Buskila D. Measuring health status in Israeli patients with fibromyalgia syndrome and widespread pain and healthy individuals: utility of the short form 36-item health survey (SF-36). Semin Arthritis Rheum 2000;29:400-8.
87. Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991;18:728-33.
88. Buskila D. Drug therapy. Baillieres Best Pract Res Clin Rheumatol 1999;81:45-55.
89. Wolfe F, Hawley DJ, Goldenberg DL, et al. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J Rheumatol 2000;27:1989-99.
90. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40.
91. Beck AT. A systematic investigation of depression. Compr Psychiatry 1961;2:163-70.
92. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33.
93. Turk DC, Monarch ES, Williams AD. Psychological evaluation of patients diagnosed with fibromyalgia syndrome: a comprehensive approach. Rheum Dis Clin North Am 2002;28:219-33.
94. Dunkl PR, Taylor AG, McConnell GG, et al. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-91.
95. Hewett JE, Buckelew SP, Johnson JC, et al. Selection of measures suitable for evaluating change in fibromyalgia clinical trials. J Rheumatol 1995;22:2307-12.
96. Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000;41:104-13.
97. Crofford LJ, Russell J, Mease P, et al. Pregabalin improves pain associated with fibromyalgia syndrome in a multicenter, randomized, placebo-controlled monotherapy trial [abstract]. Arthritis Rheum 2002;46 Suppl:S613.
98. Simms RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991;18:1558-63.
99. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58.
100. Simms RW, Goldenberg DL, Felson DT, et al. Tenderness in 75 anatomic sites. Distinguishing fibromyalgia patients from controls. Arthritis Rheum 1988;31:182-7.
101. Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40.
102. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29:1371-7.
103. Oppenheimer L, Kher U. The impact of measurement error on the comparison of two treatments using a responder analysis. Stat Med 1999;18:2177-88.
104. Witter J, Simon LS. Chronic pain and fibromyalgia: the regulatory perspective. Best Pract Res Clin Rheumatol 2003;17:541-6.
105. OMERACT 7 Website. OMERACT 7 program. [Internet] Accessed April 20, 2005. Available from: http://reuma.rediris.es/omeract/whatis/index.html
106. Rao SG, Bennett RM. Pharmacological therapies in fibromyalgia. Best Pract Res Clin Rheumatol 2003;17:611-27.
107. Bennett RM. Pharmacological treatment of fibromyalgia. J Functional Syndromes 2001;1:79-92.
108. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9.
109. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002;15:191-7.
110. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9.
111. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain 2000;4:27-35.
112. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-9.
113. Gendreau M, Hufford MR, Stone AA. Measuring clinical pain in chronic widespread pain: selected methodological issues. Best Pract Res Clin Rheumatol 2003;17:575-92.
114. Arnold LM, Lu Y, Crofford L, et al. A double-blind multicenter trial comparing duloxetine to placebo in the treatment of fibromyalgia with or without major depressive disorder [abstract]. Arthritis Rheum 2003;48 Suppl:S691.
115. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003;37:1561-5.
116. Farber L, Stratz TH, Bruckle W, et al. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron: results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res 2001;21:1-13.
117. Stratz T, Muller W. The use of 5-HT3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia? Scand J Rheumatol 2000;113 Suppl:66-71.
118. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003;60:1524-34.
119. Zimmermann M. Pathophysiological mechanisms of fibromyalgia. Clin J Pain 1991;7 Suppl 1:S8-S15.
120. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83.
121. Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-7.
122. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry 2003;160:533-40.
123. Sharma U, Iacobellis D, Glessner C, et al. Pregabalin effectively relieves pain in two studies of patients with painful diabetic peripheral neuropathy (studies 1008-14/-29) [abstract]. 19th Annual Scientific Meeting of the American Pain Society; November 2-5, 2000; Atlanta, Georgia:679.
124. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000;6:250-7.
125. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003;114:537-45.
126. Bennett RM, Gatter RA, Campbell SM, et al. A randomized trial of cyclobenzaprine and placebo in the management of fibrositis. Arthritis Rheum 1988;31:1535-42.
127. Quimby LG, Gratwick GM, Whitney CD, et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol 1989;16 Suppl 19:140-3.
128. Reynolds WJ, Moldofsky H, Saskin P, et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991;18:452-4.
129. Kranzler J, Gendreau J, Rao S. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 2002;36:165-213.
130. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-91.
131. Holman A, Neiman R, Ettlinger R. Pramipexole for fibromyalgia: the first open label, multicenter experience [abstract]. Arthritis Rheum 2002;46 Suppl:S108.
132. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31.
133. Pachas WN. Modafinil for the treatment of fatigue of fibromyalgia. Clin Rheumatol 2003;9:282-5.
134. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990;10:88-95.
135. Williams DA. Psychological and behavioral therapies in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:649-65.
136. Williams DA, Cary MA, Groner KH, et al. Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol 2002;29:1280-6.
137. Sprott H. What can rehabilitation interventions achieve in patients with primary fibromyalgia? Curr Opin Rheumatol 2003;15:145-50.
138. Richards SC, Scott DL. Prescribed exercise in people with fibromyalgia: parallel group randomised controlled trial. BMJ 2002;325:185.
139. Mannerkorpi K, Iversen MD. Physical exercise in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003;17:629-47.
140. Moldofsky H. Management of sleep disorders in fibromyalgia. Rheum Dis Clin North Am 2002;28:353-65.